Back to News & Events

Health Innovation Hub Life Science – Applications Open

Health Innovation Hub Life Science by Springboard Enterprises
Applications for the Health Innovation Hub: Life Science are open through February 24.

Springboard’s Health Innovation Hub: Life Science is a program for women-led life science and healthcare companies seeking growth funding and connections to experts and strategic partners for product development and expansion. Selected Hub companies are matched with a personal advisory team, tasked with providing a meaningful impact on the company’s next stage of growth. The program, while virtual, engages advisors and investors in a variety of in-person presentation sessions throughout the year and beyond.

Areas of focus for the program include (but are not limited to) drugs, therapeutics, diagnostics, medtech, and medical devices. Our 2020 Health Hub programming has a special focus on Women’s Health Innovation. Cost: $200 application fee ($100 is submitted by the priority deadline). If accepted: $5,000 program fee. Learn more here: sb.co/hih , Application Link Here

If you are interested or would like to refer an entrepreneur, please contact Sierra Hieronymus: sierra@sb.co

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4488
                    [post_author] => 4
                    [post_date] => 2024-10-24 10:45:00
                    [post_date_gmt] => 2024-10-24 14:45:00
                    [post_content] => 

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2024-12-05 11:35:07 [post_modified_gmt] => 2024-12-05 16:35:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3862 [post_author] => 3 [post_date] => 2021-12-07 14:43:08 [post_date_gmt] => 2021-12-07 14:43:08 [post_content] =>

Stony Brook University students: Do you have a cool business idea? Then sign up for the Stony Brook Entrepreneurs Challenge (SBEC) and compete to win funding toward making your idea into a company.

The Challenge will help you prepare to pitch your idea to a campus panel of experienced venture investors, entrepreneurs, and business services professionals - and you may be selected for NSF I-Corps Site and/or the regional competition for funding. You will have access to a New York State Small Business Development Center business advisor to help you develop your business model and practice your pitch. Open to any student/any level/any program. Learn more and apply here: https://www.stonybrook.edu/commcms/sbdc/student-entrepreneurs/2022Challenge

How the Funding Works: Prizes awarded are in the form of funds that will apply towards I-Corp support related to customer discovery, technology development, infrastructure, advice, resources, networking opportunities, and training. The I-Corps program nurtures and supports students to transition their ideas, devices, processes or other intellectual activities into the marketplace or into becoming I-Corps Team applicants.

Application due March 1st, 2022 ** Submission dates are subject to change
Competition Thursday, March 10th, 2022**
Competition dates are subject to change

[post_title] => Stony Brook Entrepreneur Challenge 2022 [post_excerpt] => Stony Brook University's 2022 Entrepreneur Challenge allows Stony Brook students to compete to win funding toward making their ideas into a company. [post_status] => publish [comment_status] => closed [ping_status] => open [post_password] => [post_name] => stony-brook-entrepreneur-challenge-2022 [to_ping] => [pinged] => [post_modified] => 2022-08-22 13:08:40 [post_modified_gmt] => 2022-08-22 13:08:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3862 [menu_order] => 28 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2801 [post_author] => 3 [post_date] => 2017-09-05 13:19:00 [post_date_gmt] => 2017-09-05 13:19:00 [post_content] => The latest CFB Newsletter has been released - Catch up on client financings, newcos, expansions, and other happenings here. Be sure to follow us on TwitterLinkedIn and Facebook for the latest Center news. [post_title] => Summer 2017 Newsletter [post_excerpt] => The latest CFB Newsletter has been released - Highlights include major client funding and contracts, the expansion of the LIBH pipeline, and CFB leadership appearing before congress to promote comprehensive, early technology development programs. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => summer-2017-newsletter [to_ping] => [pinged] => [post_modified] => 2017-09-05 13:19:00 [post_modified_gmt] => 2017-09-05 13:19:00 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2801 [menu_order] => 139 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3814 [post_author] => 4 [post_date] => 2021-09-07 16:21:33 [post_date_gmt] => 2021-09-07 16:21:33 [post_content] =>

DATE: Wednesday, September 15, 2021
TIME: 12:00 PM EDT / 9:00AM PT

Join as AdvaMed presents  “Advancing Public Health with Wearables: Strategic Development of IoMT Biosensing Lifestyle Devices” with MIDI Medical Device Development Corp. and Valencell, Inc. This webinar is presented by Christopher Montalbano, CEO, MIDI Medical Device Development Corp., and Ryan Kraudel, Vice President, Marketing, Valencell, Inc., this webinar will examine the way in which wearables advance public health when a strategic device development approach is utilized to integrate and harmonize: Lifestyle, IoMT, Biosensing, and Physiological Sensing.

In this AdvaMed Event, MIDI & Valencell will cover:
• Understand how wearable IoMT devices utilizing Bio-Sensors and Physiological Sensors translate into enhanced healthcare and wellness lifestyles.
• Learn how to optimize the selection of sensor (or sensor cluster) through a proven 4-Step approach of: User Experience Monitoring, Body Assessments, Key Body Metric Capture and Sensor Selection.
• Learn the 3-Step Innovation Roadmap™ for optimized wearable device development including: Discovery Research™, MVP R&D and AGILE Commercialization under ISO-13485.
• Review of Case Studies that demonstrate implementation of these innovation principles yielding advanced wearable IoMT healthcare sensing devices.

REGISTER HERE

[post_title] => Webinar: Advancing Public Health with Wearables: Strategic Development of IoMT Biosensing Lifestyle Devices - September 15th [post_excerpt] => On September 15 join as  MIDI Medical Device Development Corp. AdvaMed, and Valencell, Inc. present  “Advancing Public Health with Wearables: Strategic Development of IoMT Biosensing Lifestyle Devices” [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => webinar-advancing-public-health-with-wearables-strategic-development-of-iomt-biosensing-lifestyle-devices-september-15th [to_ping] => [pinged] => [post_modified] => 2021-09-20 16:02:48 [post_modified_gmt] => 2021-09-20 16:02:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3814 [menu_order] => 38 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4488 [post_author] => 4 [post_date] => 2024-10-24 10:45:00 [post_date_gmt] => 2024-10-24 14:45:00 [post_content] =>

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2024-12-05 11:35:07 [post_modified_gmt] => 2024-12-05 16:35:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 259 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.

More Information

Stony Brook Entrepreneur Challenge 2022

More Information

Summer 2017 Newsletter

More Information

Webinar: Advancing Public Health with Wearables: Strategic Development of IoMT Biosensing Lifestyle Devices – September 15th

More Information